UAlberta prostate cancer researcher and team developing 'homing beacon drugs' to target cancer cells

November 20, 2012

A medical researcher with the University of Alberta and his team just published their findings about their work on developing 'homing beacon drugs' that kill only cancer cells, not healthy ones, thanks to nano-technology.

John Lewis, the Frank and Carla Sojonky Chair in Prostate Cancer Research with the Faculty of Medicine & Dentistry, published his findings in the peer-reviewed journal, Nano Letters. He is also an associate professor in the Department of Oncology, a Fellow with the National Institute for Nanotechnology at the U of A and director of the Translational Prostate Cancer Research Group.

Lewis noted chemotherapy goes through the body and kills any cells that are dividing, even healthy ones - which is why cancer patients have immune system problems, hair loss, nausea and skin problems.

"We are developing smart drugs that determine which are the cancer cells and which aren't, then selectively kill only the cancer cells. The drugs look for a protein that is only found in cancer cells, not normal cells. This system acts like a homing beacon for tumours."

These drugs, tested to date in only animal lab models, could be used within a week of cancer diagnoses, predicts Lewis. The drugs would target cancerous cells throughout the body - attacking sneaky cancer cells that have already escaped and grown outside the site of the main tumour.

Lewis wasn't sure when these homing beacon drugs could be available for physicians to use with patients, but hopes his works paves the way for patient-centered therapies.

"If we can use 'smart' drugs that home in on tumours, we can dramatically decrease side effects for patients, lower the chance of recurrence, and hopefully increase the cancer survival rate."

Meanwhile, Lewis and his research team are continuing their work on trying to figure out what causes cancer cells to escape and spread from the main tumour site because the cells that move are different than the ones in the main tumour. They have pinpointed numerous genes that set these 'moving' cancer cells apart from the ones that stay put. Based on this research, they have come up with a drug that uses a 'tumour glue' to prevent these moving cancer cells from breaking apart from the main tumour, which prevents the spread of the cancer. Using knowledge gained from the 'tumour glue' drug, Lewis and his team are working to develop new blood tests to predict whether prostate and other cancers will spread.
-end-


University of Alberta Faculty of Medicine & Dentistry

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.